Abstract
DL-α-Methyl-α-hydrazino-3,4-dihydrophenylpropionlc acid (HMD) and [N1-(DL-seryl)-N2-(2,3,4-trihydroxybenzyl) hydrazine] (Ro 4-4602), two known inhibitors of aromatic amino acid decarboxylase (dopa decarboxylase), were investigated for their effect upon some centrally mediated actions of l-dopa. HMD enhanced the ability of l-dopa to increase motor activity and irritability in mice and to increase motor activity in rats. In addition, HMD enhanced the reversal by L-dopa of reserpine-induced hypothermia, suppression of locomotion and ptosis. Enhancement of the pharmacologic actions of L-dopa by HMD was associated with enhanced brain dopamine levels. In contrast, the vomiting response to L-dopa in dogs and pigeons was attenuated by treatment with HMD. Low doses of Ro 4-4602 (1-125 mg/kg) potentiated l-dopa reversal of the locomotor suppressant and ptotic actions of reserpine; whereas, high doses (125-625 mg/kg) inhibited these actions of L-dopa. It is concluded that decarboxylase inhibitors can either inhibit or potentiate the central actions of i.-dopa depending upon whether they reach the brain sites where L-dopa acts.
Footnotes
- Received August 13, 1969.
- Accepted November 26, 1969.
- © 1970, by The Williams & Wilkins Co.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|